SCHEMBL14744817

SCHEMBL14744817

CCc1c(-c2cc3cc(F)c(C)cc3[nH]2)[nH]c(=O)c(C(=O)O)c1O

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 6/20 0.33
KDM4E B2RXH2 5/20 0.33
TSHR P16473 4/20 0.33
ALDH1A1 P00352 4/20 0.33
HPGD P15428 2/20 0.33
TP53 P04637 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
CYP1A2 P05177 1/20 0.32
EIF4A3 P38919 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
DAO P14920 1/20 0.32
FFAR1 O14842 1/20 0.31
PPARG P37231 1/20 0.31
LDHA P00338 1/20 0.30
LDHB P07195 1/20 0.30
DHODH Q02127 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745749 0.86 BRD4 (0.35) HSD17B10KDM4ETSHRALDH1A1POLB
SCHEMBL14745557 0.83 KDM4E (0.44) HSD17B10KDM4ETSHRALDH1A1HPGD
SCHEMBL14745595 0.80 FFAR1 (0.42) HSD17B10KDM4ETSHRALDH1A1HPGD
SCHEMBL14745407 0.80 DAO (0.51) TSHRALDH1A1POLBMAPTNPSR1
SCHEMBL14746103 0.78 DAO (0.35) HSD17B10KDM4ETSHRALDH1A1HPGD
SCHEMBL14744741 0.78 GRIN2D (0.30) DAO
SCHEMBL14745316 0.77 FFAR1 (0.44) FFAR1PPARG
SCHEMBL14744838 0.77 DAO (0.43) KDM4EALDH1A1HPGDDAOFFAR1
SCHEMBL14745184 0.77 KDM4E (0.44) HSD17B10KDM4ETSHRALDH1A1HPGD
SCHEMBL14745708 0.75 FFAR1 (0.42) HSD17B10KDM4ETSHRALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US claimed
WO-2016039937-A1 BICYCLIC AND TRICYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-03-17 WO claimed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US claimed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP claimed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO claimed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
WO-2016039937-A1 BICYCLIC AND TRICYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-03-17 WO disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP HSD17B10 2349/4885KDM4E 4305/4885TSHR 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.